Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study Meeting Abstract

  

Authors:	Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; Diab, V.; Werner, K.; Rispoli, J.; Sams, A.; Verducci, D.; Jones, K.; Harrison, A.; Chansakul, A.; Rustad, E. H.; Yellapantula, V.; Maura, F.; Landau, H. J.; Scordo, M.; Chung, D. J.; Shah, G.; Lahoud, O. B.; Thoren, K.; Murata, K.; Ramanathan, L.; Arcila, M. E.; Ho, C.; Roshal, M.; Dogan, A.; Devlin, S. M.; Giralt, S.; Korde, N.
Abstract Title:	Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
Meeting Title:	61st Annual Meeting and Exposition of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	134
Issue:	Suppl. 1
Meeting Dates:	2019 Dec 7-10
Meeting Location:	Orlando, FL
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2019-11-13
Language:	English
ACCESSION:	WOS:000518218500895
DOI:	10.1182/blood-2019-126378
PROVIDER:	wos
Notes:	Meeting Abstract: 862 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/171865